Evidence map›Paper›PMID 40703291›Full record

ArticleFrontiers in medicine2025

Artificial liver plasma adsorption improves survival in elderly patients with severe pneumonia: a retrospective cohort study.

Richai Chen, Jiaqian Jin, Sainan Zhang, Jiajun Wu, Qiangqiang Xiang, Xuanhao Lin, Danhua Zhu, Mengfei Zhu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Richai Chen *Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan (Hangzhou) Hospital Affiliated to Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China.
Jiaqian Jin *Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Sainan ZhangKey Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan (Hangzhou) Hospital Affiliated to Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China.
Jiajun WuKey Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan (Hangzhou) Hospital Affiliated to Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China.
Qiangqiang XiangState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Jiangsu, China.
Xuanhao LinZhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Danhua ZhuState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Jiangsu, China.
Mengfei ZhuKey Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan (Hangzhou) Hospital Affiliated to Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To assess the therapeutic efficacy of artificial liver plasma adsorption (ALPA) in patients with severe pneumonia. Methods: This retrospective study enrolled 151 patients meeting severe pneumonia diagnostic criteria who were admitted to the intensive care unit at Shulan Hospital, Hangzhou, China, between January 2020 and December 2024. Participants were allocated to either: (1) the ALPA intervention group ( Results: No statistically significant differences were observed between the two groups regarding WBC, CRP, PCT, or IL-6 levels at baseline (all Conclusion: Artificial liver plasma adsorption (ALPA) therapy demonstrates significant clinical efficacy by effectively suppressing inflammatory markers (e.g., IL-6, CRP) and attenuating cytokine storm progression. This treatment significantly reduces mortality and prolongs survival time in elderly patients with severe pneumonia.

Indexed as

artificial livercytokine stormelderly patientsinterleukin-6severe COVID-19 pneumonia

Identifiers

PMID40703291
PMCPMC12283744

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.